TIL Therapy in Lung Cancer: Current Progress and Perspectives
Advanced Science · 2024-12 · 11 (46)
DOI: 10.1002/advs.202409356 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Science, online erschienen am 18.10.2024. Verfasst von Weilei Hu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese A…. Hauptthemen laut MEDLINE: Lung Neoplasms, Lymphocytes, Tumor-Infiltrating, Immunotherapy, Adoptive. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 155 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Research & Development Program of China, National Natural Science Foundation of China, Basic Frontier Scientific Research Program of Chinese Academy of Science.
Abstract (Originalsprache)
Lung cancer remains the most prevalent malignant tumor worldwide and is the leading cause of cancer‐related mortality. Although immune checkpoint blockade has revolutionized the treatment of advanced lung cancer, many patients still do not respond well, often due to the lack of functional T cell infiltration. Adoptive cell therapy (ACT) using expanded immune cells has emerged as an important therapeutic modality. Tumor‐infiltrating lymphocytes (TIL) therapy is one form of ACT involving the administration of expanded and activated autologous T cells derived from surgically resected cancer tissues and reinfusion into patients and holds great therapeutic potential for lung cancer. In this review, TIL therapy is introduced and its suitability for lung cancer is discussed. Then its historical and clinical developments are summarized, and the methods developed up‐to‐date to identify tumor‐recognizing TILs and optimize TIL composition. Some perspectives toward future TIL therapy for lung cancer are also provided.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, 310024, China.
- Key Laboratory of Multi-Cell Systems, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai, 200031, China.
- University of Chinese Academy of Sciences, Beijing, 100049, China.
- School of Life Science and Technology, Shanghai Tech University, Shanghai, 200120, China.
ORCID-Profile: Hongbin Ji
Förderung
- Key Research & Development Program of China
- National Natural Science Foundation of China
- Basic Frontier Scientific Research Program of Chinese Academy of Science
Zitieren
APA
Hu, W., Bian, Y., & Ji, H. (2024). TIL Therapy in Lung Cancer: Current Progress and Perspectives. Advanced Science, 11(46). https://doi.org/10.1002/advs.202409356
Vancouver
Hu W, Bian Y, Ji H. TIL Therapy in Lung Cancer: Current Progress and Perspectives. Advanced Science. 2024;11(46). doi:10.1002/advs.202409356
BibTeX
@article{Hu2024,
author = {Hu, Weilei and Bian, Yifei and Ji, Hongbin},
title = {TIL Therapy in Lung Cancer: Current Progress and Perspectives},
journal = {Advanced Science},
year = {2024},
volume = {11},
number = {46},
doi = {10.1002/advs.202409356}
}
EUVIMED